Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. PPM Ventures and Triton – acquisition of Pharmacia Diagnostics
Mandate

PPM Ventures and Triton – acquisition of Pharmacia Diagnostics

May 12, 2005

Triton, the European private equity firm, and PPM Ventures Ltd, the private equity business within Prudential Corporation plc, the UK financial services group, has agreed to acquire Pharmacia Diagnostics AB, the Swedish based in-vitro allergy and autoimmune diagnostic testing business of Pfizer Inc, the US-based health care company, for USD 575m.

Vinge acted for Triton and PPM Ventures Ltd.

Johan Cederlund, Christina Kokko (responsible partners)
Sara Mindus (associate)

Related

Vinge advises Röko AB (publ) in connection with the establishment of its MTN programme

 Vinge has advised Röko AB (publ) ("Röko") on the establishment of a medium-term note programme (the "MTN Programme") with a framework amount of SEK 5 billion.
November 13, 2026

Vinge advises Telavox on the sale of its Nordic customer base to Telia

 Vinge has advised Telavox AB (“Telavox”) on the sale of Telavox’s Nordic customer base for business services to Telia Company AB (“Telia”). The customer base comprises approximately 24,000 business customers and 325,000 end users in Sweden, Denmark, Finland, and Norway. The purchase price amounts to SEK 3.8 billion plus a potential additional earn-out.
November 13, 2026

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026